CLRB
Cellectar BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
CLRB vs peer average
79/100
CLRB vs. peer average (B vs. D)
Grade spread
A 3 · D 1 · F 7
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
BCTX is the first available peer comparator.
BriaCell Therapeutics offers a closer oncology-development comparison than the other size-matched names, with sentiment often tied to trial updates and capital access. Even so, it remains a loose peer rather than a direct operating analogue for iopofosine.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CLRB
Cellectar Biosciences
BCTX
BriaCell Therapeutics
Grade
B
F
Momentum
69
2
Value
41
41
Sentiment
58
-
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs BCTX
CLRB / BCTX
Grade Position
Above peers
CLRB vs. peer average (B vs. D)
79/100
Momentum
69
CLRBValue
41
CLRBSentiment
58
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CLRB
BCTX is the first peer returned for this comparison set.